急性髓系白血病中FLT3-JMD点突变的预后、生物学及结构意义:Alliance研究分析
分析1660例初诊急性髓系白血病患者,FLT3-JMD突变占2%,以点突变为主。FLT3-JMD突变患者复发率高于FLT3-TKD且无病生存期更短,但复发率、无病生存和总生存与FLT3-ITD阳性患者无显著差异。体外实验显示FLT3-JMD点突变可转化造血细胞并对I型和II型FLT3抑制剂反应良好。
要点
- 1660例初诊AML中FLT3-JMD突变占2%,以点突变为主。
- FLT3-JMD突变患者复发率高于FLT3-TKD,无病生存期更短。
- FLT3-JMD突变患者复发率、无病生存和总生存与FLT3-ITD阳性无显著差异。
核心结论
- FLT3-JMD点突变患者为不常见但重要的亚群,具有独特分子和生物学特征,可能从FLT3抑制剂获益。
研究设计与样本
- 分析1660例初诊急性髓系白血病患者,检测FLT3-JMD突变。
- 进行体外实验观察FLT3-JMD点突变对造血细胞的转化作用及对FLT3抑制剂的反应。
- 采用分子动力学模拟探索JMD点突变相对野生型FLT3的构象变化。
主要发现
- FLT3-JMD突变(多为点突变)在1660例患者中占2%。
- FLT3-JMD突变患者复发率高于FLT3-TKD患者,无病生存期短于FLT3-TKD患者。
- FLT3-JMD突变患者复发率、无病生存和总生存与FLT3-ITD阳性患者无显著差异。
- 体外实验显示FLT3-JMD点突变可转化造血细胞,并对I型和II型FLT3抑制剂反应良好。
- 分子动力学模拟显示JMD点突变域运动受限、门控开口更宽,可能增强药物结合,变构通路增加提示与其他残基相互作用减少。
临床怎么用
- 作者认为FLT3-JMD点突变患者可能从FLT3抑制剂获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The FLT3 gene frequently undergoes mutations in acute myeloid leukemia (AML), with internal tandem duplications (ITD) and tyrosine kinase domain (TKD) point mutations (PMs) being most common. Recently, PMs and deletions in the FLT3 juxtamembrane domain (JMD) have been identified, but their biological and clinical significance remains poorly understood. We analyzed 1660 patients with de novo AML and found FLT3-JMD mutations, mostly PMs, in 2% of the patients. Patients with FLT3-JMD mutations had a higher relapse rate and shorter disease-free survival than those with FLT3-TKD, whereas their relapse rate, disease-free and overall survival were not significantly different from those of FLT3-ITD-positive patients. In vitro experiments showed that FLT3-JMD PMs transformed hematopoietic cells and responded well to type I and II FLT3 inhibitors. Molecular dynamics simulations were used to explore the conformational changes of JMD PMs relative to wild-type FLT3. These mutations exhibited constrained domain motions with wider gate openings, potentially enhancing drug binding. Altered residue interactions and structural changes shed light on their unique functional mechanisms, with increased allosteric pathways suggesting reduced interactions with other residues. We conclude that patients with FLT3-JMD PMs represent uncommon but important subset with distinct molecular and biological features, and may benefit from FLT3 inhibitors.
引用
- Anabtawi N, Nicolet D, Alotaibi N, et al. Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies. Leukemia. 2025. PMID: 39806020. doi:10.1038/s41375-024-02498-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。